Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan W Day

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Journal of Neuro-Oncology|November 25, 2019
Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytomaKok-Siong Chen, Caitlin R Bridges, Zorana Lynton, et al.
Journal of Medicinal Chemistry|February 17, 2017
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in GlioblastomaQingqing Zhou, Athena F Phoa, Ramzi H Abbassi, et al.
Cancer Immunology, Immunotherapy : CII|May 15, 2017
Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastomaRoger Gilabert-Oriol, Sebastian G B Furness, Brett W Stringer, et al.
Oncogene|December 20, 2024
CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancersPrahlad V Raninga, Bijun Zeng, Davide Moi, et al.
Therapeutic Advances in Medical Oncology|October 5, 2020
Clinicopathologic significance of nuclear HER4 and phospho-YAP(S<sup>127</sup>) in human breast cancers and matching brain metastasesPriyakshi Kalita-de Croft, Malcolm Lim, Haarika Chittoory, et al.
Oncogene|March 3, 2025
Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancersPrahlad V Raninga, Bijun Zeng, Davide Moi, et al.
Cell Death Discovery|April 17, 2021
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cellsAriadna Recasens, Sean J Humphrey, Michael Ellis, et al.
Biochemical Pharmacology|November 1, 2015
Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signallingAthena F Phoa, Stephen Browne, Fadi M S Gurgis, et al.
International Journal of Molecular Sciences|April 30, 2021
A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in GlioblastomaSakthi Lenin, Elise Ponthier, Kaitlin G Scheer, et al.
Cells|January 25, 2020
Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D CultureRochelle C J D'Souza, Carolin Offenhäuser, Jasmin Straube, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Journal of Neuro-Oncology|November 25, 2019
Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytomaKok-Siong Chen, Caitlin R Bridges, Zorana Lynton, et al.
Journal of Medicinal Chemistry|February 17, 2017
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in GlioblastomaQingqing Zhou, Athena F Phoa, Ramzi H Abbassi, et al.
Cancer Immunology, Immunotherapy : CII|May 15, 2017
Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastomaRoger Gilabert-Oriol, Sebastian G B Furness, Brett W Stringer, et al.
Oncogene|December 20, 2024
CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancersPrahlad V Raninga, Bijun Zeng, Davide Moi, et al.
Therapeutic Advances in Medical Oncology|October 5, 2020
Clinicopathologic significance of nuclear HER4 and phospho-YAP(S<sup>127</sup>) in human breast cancers and matching brain metastasesPriyakshi Kalita-de Croft, Malcolm Lim, Haarika Chittoory, et al.
Oncogene|March 3, 2025
Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancersPrahlad V Raninga, Bijun Zeng, Davide Moi, et al.
Cell Death Discovery|April 17, 2021
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cellsAriadna Recasens, Sean J Humphrey, Michael Ellis, et al.
Biochemical Pharmacology|November 1, 2015
Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signallingAthena F Phoa, Stephen Browne, Fadi M S Gurgis, et al.
International Journal of Molecular Sciences|April 30, 2021
A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in GlioblastomaSakthi Lenin, Elise Ponthier, Kaitlin G Scheer, et al.
Cells|January 25, 2020
Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D CultureRochelle C J D'Souza, Carolin Offenhäuser, Jasmin Straube, et al.
Pageof 8